Shah Divya
Internal Medicine, University of Arizona College of Medicine - Phoenix, Phoenix, USA.
Cureus. 2023 Dec 11;15(12):e50333. doi: 10.7759/cureus.50333. eCollection 2023 Dec.
Eosinophilic cellulitis (EC) or Wells' syndrome, characterized by its rarity and diverse clinical presentations, presents substantial challenges in diagnosis and treatment. This case study details the challenging journey of a 48-year-old woman with non-specific skin lesions, showcasing the persistence of dermatitis despite exhaustive attempts at various interventions outlined in the literature. In the absence of a consensus on optimal management for EC, this study introduces a transformative solution through the utilization of dupilumab, a monoclonal antibody targeting interleukin-4/interleukin-13. The patient experienced marked improvement and resolution of dermatitis following dupilumab treatment alone, highlighting the efficacy of this targeted immunomodulatory approach in cases refractory to traditional therapies. This pioneering case underscores the significance of exploring innovative treatments and suggests dupilumab as a potential breakthrough therapeutic option in addressing EC refractory to standard medical management.
嗜酸性粒细胞性蜂窝织炎（EC）或威尔斯综合征，因其罕见性和多样的临床表现而具有特征，在诊断和治疗方面存在重大挑战。本病例研究详细描述了一名48岁患有非特异性皮肤病变女性的艰难历程，展示了尽管按照文献中概述的各种干预措施进行了详尽尝试，但皮炎仍持续存在。在缺乏关于EC最佳管理的共识的情况下，本研究通过使用度普利尤单抗（一种靶向白细胞介素-4/白细胞介素-13的单克隆抗体）引入了一种变革性解决方案。仅在度普利尤单抗治疗后，患者的皮炎就有了显著改善并得到缓解，突出了这种靶向免疫调节方法在传统疗法难治性病例中的疗效。这个开创性的病例强调了探索创新治疗方法的重要性，并表明度普利尤单抗作为一种潜在的突破性治疗选择，可用于治疗对标准药物治疗难治的EC。
